Fail Safe Cell Therapy

1-888-613-6862
info@pancella.com

A radiolabeled antibody targeting CD123(+) leukemia stem cells – initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML.

Jeffrey V Leyton, Catherine Gao, Brent Williams, Armand Keating, Mark Minden, Raymond M Reilly
Leuk Res Rep 2015 18;4(2):55-9. Epub 2015 Sep 18.

Radioimmunotherapy (RIT) with anti-CD123 monoclonal antibody CSL360 modified with nuclear translocation sequence (NLS) peptides and labeled with the Auger electron-emitter, (111)In ((111)In-NLS-CSL360) was studied in the prevalent NOD/SCID mouse AML engraftment assay. Significant decreases in CD123(+) leukemic cells and impairment of leukemic stem cell self-renewal were achieved with high doses of RIT….

–Source: https://www.ncbi.nlm.nih.gov/pubmed/26500848

Sorry, comments are closed for this post.